Evaluating the impact of RSV immunisation strategies on antibiotic use in England

Katherine E. Atkins, David Hodgson, Mark Jit, Nicholas G. Davies

Corresponding author. Address for correspondence: Katherine E. Atkins, Centre for Global Health, Usher Institute, MacKenzie House
30 West Richmond Street, University of Edinburgh, EH8 9DX, United Kingdom. E-mail: katherine.atkins@ed.ac.uk

Author affiliations: London School of Hygiene and Tropical Medicine, London, UK (K.E. Atkins, D. Hodgson, N.G. Davies); University of Edinburgh, Scotland, UK (K.E. Atkins).

Abstract

With a sizable fraction of primary care antibiotics prescribing attributable to RSV, the promising suite of prophylactic pharmaceuticals against could reduce the need for antibiotics in addition to controlling respiratory disease. To assess the potential impact of RSV vaccines on the reduction in primary care antibiotic prescribing in England, we integrate results from a dynamic transmission model of RSV and a statistical attribution framework. Under base case assumptions, targeting children aged 5-14 years reduces antibiotic prescribing by 10.9 (8.0-14.2) antibiotic courses per 10,000 person years. This reduction in antibiotic use would gain 128 DALYs and avert 51,000 GBP associated with infections caused by drug resistant bacteria. Seasonally administering monoclonal antibodies (mAbs) to high risk infants under 6 months is the most efficient strategy (reducing per person year antibiotic prescribing by 2.6 (1.9-3.3) antibiotic courses per 1,000 mAb courses).

Introduction

Vaccines against viral pathogens have been suggested as a novel means to reduce antibiotic resistance (1). By reducing the number of viral infections, fewer antibiotics would be used either inappropriately against viral disease, as a precautionary measure for non-specific symptoms, or to treat bacterial co-infections (2,3). Consequently, this reduction in antibiotic use would exert less selection for resistance on highly prevalent commensal bacteria that can lead to invasive disease.

Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infections in young children globally (4). RSV can cause mild upper respiratory tract symptoms across all age groups and these infections can often result in primary care visits (5). Data from high income countries suggest that antibiotic prescribing is common amongst primary care visits attributable to RSV infection, and consequently, reducing RSV infections may be beneficial to control antibiotic resistance across highly prevalent bacterial species (6,7). Currently there are seven RSV vaccine formulations in Phase III clinical trials, including those targeting children, pregnant women, and the elderly (8). However, there are currently no estimates of the potential impact of RSV vaccines on preventing either antibiotic prescribing or antibiotic resistance.

In this study we evaluate the likely impact of the new generation of RSV vaccine strategies on antibiotic prescribing in England, a high income setting, and use these predictions to quantify the reduction in antibiotic resistance outcomes.

50 **Methods**

51

52 *Literature review*

53 We searched Pubmed using the terms: ("Respiratory Syncytial Virus, Human"[MeSH Terms]
54 OR "Respiratory Syncytial Virus Infections"[MeSH Terms]) AND ("antibiotic" OR "antibiotics"
55 OR "antimicrobial" OR "antimicrobials") up to 3 November 2021. We included all those studies
56 that evaluated the impact of an RSV vaccine on antibiotic use, or that estimated antibiotic use in
57 the community, outpatient or long term care facility settings that was either i) coincident with
58 respiratory infection symptoms with virologically confirmed RSV infection, or ii) attributed to
59 RSV via statistical methods. We excluded all studies that reported antibiotic use only in
60 hospitalised individuals or those attending emergency care, and excluded all review and
61 commentary articles. We included patients of all ages and in any risk group.

62

63 *Vaccine strategies*

64 We evaluated the impact of 12 potential RSV immunisation strategies on antibiotic prescribing
65 rates in England. Specifically, we predicted the impact of a suite of vaccine strategies relying on
66 vaccines that are currently under evaluation in clinical trials that can be administered via age
67 groups or risk groups feasibly and affordably (9,10). These strategies are: vaccination of infants
68 at two months (seasonally - VAC INF S, or year round - VAC INF A); vaccination during the
69 third trimester of pregnancy (seasonally - MAT S, or year-round - MAT A); seasonal vaccination
70 of toddlers aged 2-4 years (VAC 2-4 S), primary school children aged 5-9 years (VAC 5-9 S) or
71 primary and secondary school children aged 5-14 years (VAC 5-14 S); and, seasonal
72 administration of long-acting monoclonal antibodies. These monoclonal antibody strategies are,

73 in increasing order of number of doses given: very high risk infants under 8 months currently
74 eligible for Palivizumab (MAB VHR S) (11), high risk infants at birth as well as those currently
75 eligible for Palivizumab (MAB HR S), high risk infants under 6 months as well as those
76 currently eligible for Palivizumab (MAB HR S+), all infants at birth (MAB ALL S), or all
77 infants under 6 months (MAB ALL S+).
78
79 We considered the efficacy against infection of long acting monoclonal antibodies and of
80 maternal vaccination to be consistent with respective clinical trials, but that vaccine efficacy
81 against infection in infants, toddlers and older children is consistent with natural infection, in the
82 absence of clinical trial data (9) (**Table 2**). We assumed that vaccine uptake was consistent with
83 other vaccine strategies delivered to the same age groups, and the monoclonal antibody uptake
84 was the same as that for Palivizumab (9). We assumed that all vaccine strategies were
85 administered in addition to Palivizumab while all monoclonal antibody strategies replaced
86 Palivizumab.
87
88 *Antibiotic courses averted*
89 We first calculated the age-specific reduction in the number of antibiotic courses per 1000 person
90 years due to each of these 12 vaccine strategies by multiplying the age-specific fraction of
91 primary case visits averted with the age-specific number of primary care visits attributable to
92 RSV that result in an antibiotic prescription.
93
94 *i) Primary case visits averted*: We calculated the average proportional reduction in primary care
95 visits for 0-5 months, 6-23 months, 2-4 years, 5-17 years, 18+ years using a dynamic

96 transmission model for RSV in England (9). We calculated the average reduction across a ten
97 year time horizon after implementation of each immunisation strategy relative to the current
98 status quo, Palivizumab administered seasonally to very high risk infants (9). For each
99 intervention, we generated 1,000 estimates that captured uncertainty in the RSV incidence and
100 the intervention impact via the joint posterior model parameter distribution using the efficacy
101 and uptake parameter estimates (**Table 2**).
102
103 *ii) RSV-attributable primary care antibiotic prescribing:* In our base case analysis, we used
104 estimates from a previous statistical attribution model that calculated the prescribing rates in
105 primary care attributable to RSV in England and Wales (calculated as the number of antibiotic
106 courses per 100,000 person years for the age groups 0-5mo. 6-23mo, 2-4y and 5-17y) (6). For
107 each of the five age groups, we assumed the point value and confidence intervals to be from a
108 triangular distribution with a mode and 95% confidence intervals, respectively and generated
109 1,000 samples from these distributions (**Table 3**).
110
111 We performed sensitivity analyses on the RSV-attributable antibiotic prescribing. Specifically,
112 we used an alternative study from Scotland that calculated both the total primary care
113 prescriptions and the fraction of these prescriptions attributable to RSV for infants for 0-11mo
114 and for 1-4yr (7) (**Table 3**). To calculate the proportion of RSV-attributable prescriptions for 5-
115 17y we assumed that the ratio of prescribing for those aged 5-17y to those aged 2-4y was the
116 same as the base case study. In the first sensitivity analysis we assumed that the antibiotic
117 prescribing rate in those aged 18+y was the same as that for those aged 5-17y. In the second
118 sensitivity analysis we assumed that there was no RSV-attributable antibiotic prescribing for

119 those aged 18+ (**Table 3**). We calculated the results stratified by the same age groups as our base
120 case analysis, weighting by 2019 Scottish age group population sizes, and generated 1,000
121 simulations as per the base case analysis.
122
123 *Impact of averted prescribing*
124 We first converted the averted number of antibiotic courses to averted defined daily doses
125 (DDD) (assumed to be seven per antibiotic course (12)). We then used a previously published
126 statistical model to calculate the population impact of the averted DDD on resistant infections,
127 and calculated the health gain from these averted resistant infections in terms of the averted
128 deaths, and the Disability-Adjusted Life Years gained (13,14). We then calculated the averted
129 cost of these drug resistant infections (in 2020 GBP) by multiplying the number of averted drug
130 resistant infections by the 2020 cost of a drug resistant infection. This cost was assumed to be
131 $1415 in 2015 USD (15), deflated to 2014 prices, before converting to 2014 GBP using
132 equivalent health purchasing power (16), then inflated to 2020 prices at a rate of 2.3% per year
133 (17) giving a price of £586.83 per drug resistant infection.
134
135 *Code and analysis*
136 We conducted our analysis using R (18), plotted our results using ggplot2, and all code is
137 available at github.com/katiito/rsvvaccines_amr.
138
139 **Results**
140 Our search found 285 articles, 57 of which were excluded after title and abstract screening. After
141 full text review, ten articles met our inclusion criteria (**Table 1**). Only one of these studies

142 evaluated the impact of RSV infection on antibiotic use in a low income setting (19), with the
143 others conducted in the US and Europe. Studies covered a range of ages, with estimates from
144 either children, all household members, or the elderly. Studies provided estimates of one or more
145 of the following: the rate of RSV-associated antibiotic use in population, the rate or proportion of
146 antibiotic use per RSV episode, and the rate or proportion of RSV episodes per antibiotic course.
147 Studies were either retrospective or prospective cohorts or statistical attributable models.
148 Differences in study design and reporting prevent straightforward comparisons between the
149 estimates. For our analysis, we use the two study estimates that are both in the UK, and because
150 of their similar study design, study population and age-stratification, lead to more comparable
151 estimates.
152
153 We first assessed the impact of RSV immunisation strategies on primary care visits. Our model
154 found that only four intervention strategies were able to reduce primary care visits by more than
155 5% in non-targeted age groups through herd protection: seasonal administration of monoclonal
156 antibodies to <6 months (MAB ALL S+), seasonal (VAC INF S) or year-round (VAC INF A)
157 administration of infant vaccination, and seasonal administration of vaccine to 5-14y (VAC 5-14
158 S). Conversely, many strategies did not reduce GP visits by 5% within the target age group
159 (**Table 4**).
160
161 There was a substantial difference in the annual number of antibiotic courses averted across both
162 age group and intervention strategy. For infants <6 months, the largest number of courses averted
163 were for mAb strategies administered to all infants, and for any of the infant or maternal vaccine
164 strategies. Similarly, those aged 6-23 months benefitted from mAb or infant vaccine strategies.

165 For older children, only vaccines that targeted their age group led to substantial benefits in
166 annual averted antibiotic courses (**Figure 1**).
167
168 The strategies that performed best at reducing antibiotic prescribing across the whole population
169 were, in decreasing order: 5-14y vaccination (a reduction of 10.9, 95% CI: 8.0-14.2 antibiotic
170 courses per 10,000 person years; VAC 5-14 S), 2-4y vaccination (6.6, 95% CI: 5.0-8.3; VAC 2-4
171 S), seasonal monoclonal antibody administration to all infants under 6 months (6.0, 95% CI:4.4-
172 7.5; MAB ALL S+), then 5-9y vaccination (5.0, 95% CI: 3.6-6.7; VAC 5-9 S), then year-round
173 infant vaccine (4.6, 95% CI: 3.8-5.5; VAC INF A). The remaining strategies averted on average
174 fewer than 3 antibiotic courses per 10,000 person years across all simulations (**Figure 1**). The
175 best performing strategy of seasonal child and adolescent vaccination (VAC 5-14 S) averted
176 0.23% (95% CI: 0.16-0.29%) of the total antibiotic prescriptions (for any indication or aetiology)
177 recorded in 2018. Monoclonal antibody administration to high risk infants most efficiently
178 reduced antibiotic use per intervention course, reducing the number of antibiotic courses per
179 person year by 2.6 (95% CI: 1.9-3.3) per 1,000 mAb doses (**Figure 1**).
180
181 We calculated that seasonally vaccinating those aged 5-14 years (VAC 5-14 S) would lead to an
182 annual gain of 128 (95% CI: 91-165) DALYs due to averting drug-resistant bacterial infections.
183 This annual gain in DALYs is attributable to 86 (95% CI:61-111) infections and 4 (95% CI:3-6)
184 deaths caused by drug-resistant bacteria (**Figure 2**). The annual averted cost of these drug
185 resistant cases, which would be in addition to averted costs due to RSV disease, is £51,000 (95%
186 CI:36,000-65,000) in 2020.
187

188 The sensitivity analyses projected less impact of RSV vaccines on antibiotic use. Under the first
189 sensitivity analysis, the 5-14y vaccine strategy (VAC 5-14 S) averts 5.8 (95% CI: 3.1-9.5)
190 antibiotic courses per 10,000 person years, equivalent to around 0.1% (95% CI: 0.06-0.2%) of all
191 prescriptions in 2018 (**Figure S1, S2**). Under the alternative assumptions in the presence of no
192 RSV-attributable prescribing over the age of 17 years, we found that toddler vaccination and
193 child/adolescent vaccination were equally impactful in averting antibiotic courses. For
194 comparison, under these most conservative assumptions, the child and adolescent strategy averts
195 2.5 (95% CI: 1.4-4.0) antibiotic courses per 10,000 person years, leading to a total annual gain of
196 29 DALYs (95% CI: 17-46) (**Figure S3, S4**).
197
198

Discussion

Our study found that under the highest estimated RSV-attributable prescribing rates, the most impactful child and adolescent vaccination strategy was able to avert a quarter of a percent of the annual antibiotic prescriptions in England. This effect is limited due to a combination of factors: first, vaccination targeting the young will not substantially decrease the number of primary care visits across older age groups, so the average impact across the entire population is small. Second, antibiotic use attributable to RSV decreases with age, dropping from 20% for those under 6 months to 4% for ages 5-17 years. Finally, the assumed efficacy and uptake of the vaccine limit the total reduction in primary care visits.

Our analysis found that the combination of age-targeted RSV vaccination and age-specific variability in the RSV-associated antibiotic prescribing rates led to substantial differences in the potential reduction in antibiotic prescribing across age groups. For example, the most impactful strategy for the youngest age group, administering monoclonal antibodies to those under 6 months, would avert antibiotic prescriptions at a rate 30 times higher than is estimated in the entire population. Further, the size of the immunisation strategy largely predicts the total impact of averting antibiotic use, with the notable exception of vaccinating toddlers aged 2-4 years and monoclonal antibody administration of monoclonal antibodies to those aged less than 6 months. The impact of these two strategies across the entire population was relatively impactful due to both high coverage and efficiency.

221 Given increasing interest in the use of vaccines, including viral vaccines, to control antibiotic
222 resistance, it is advisable to consider averted resistance outcomes in the economic evaluation of
223 vaccines. However for RSV, our analysis suggests there would be a modest gain in DALYs
224 attributable to averted drug resistant infections. Specifically, even the most impactful programme
225 under the most optimistic scenario, a seasonal childhood vaccination for 5-14 year olds, would
226 save £51K and 128 DALYs in drug resistant outcomes. Conversely, if this programme were to
227 be administered at £20 per vaccine course, it would cost over £81 million and need to gain 4,100
228 quality-adjusted life years (QALYs) to be cost-effective in England (assuming a willingness-to-
229 pay of £20,000/QALY). Therefore, the main benefit of RSV vaccination is likely to be in
230 averting RSV itself, rather than averting antibiotic resistance due to by-stander selection. As
231 noted previously (13), the analysis calculating antibiotic resistant outcomes assumes a
232 counterfactual of no infection. Any deviation from this assumption would further reduce the
233 impact of RSV vaccination on resistant outcomes (20).
234
235 Our results suggest that with a fixed uptake and efficacy of a vaccine, the impact of an RSV
236 immunisation strategy on antibiotic prescribing is largely driven by the rate of antibiotic use
237 attributable to RSV. For countries where antibiotic use due to RSV is high, the benefits of an
238 RSV vaccine programme could be much larger and conceivably alter the cost-effectiveness of
239 vaccination strategies. Indeed, a study in Maela, on the Thailand-Myanmar border found that
240 young children who presented with antibiotic-indicated pneumonia who were later confirmed as
241 RSV-infected did so at over twice the rate (240 courses given per 1000 children) (19) as children
242 of the same age prescribed antibiotics in primary care attributable to RSV in the UK (110 courses
243 given per 1000 children) (6). As the clinical presentation and antibiotic prescribing was not

comparable between the two studies, it is likely that a vaccine targeted at children in Maela would have more than double the impact on reducing antibiotic use compared with children in the UK. Moreover, it is not only the rate of RSV-associated symptoms that determines the effect of an RSV vaccine on antibiotics, but the magnitude of total antibiotic use. For settings where over-the-counter, unregulated antibiotic use comprise the majority of drug consumption – and where, as a consequence, multidrug resistance will be higher – the benefits of RSV vaccines on controlling drug resistance will likely be substantially larger.

Contributors

KEA conceived the study. KEA did the literature review and data analysis. KEA, DH, MJ, and NGD interpreted the data. DH reviewed the code. KEA wrote the manuscript, which was critically revised by DH, MJ, and NGD.

Funding

N.G.D. and M.J. were funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Immunisation (HPRU-2019-NIHR200929) at the London School of Hygiene and Tropical Medicine and M.J. was funded by the NIHR HPRU in Modelling & Health Economics (HPRU-2019-NIHR200908) at Imperial College and the London School of Hygiene and Tropical Medicine, both in partnership with the UK Health Security Agency. The views expressed are those of the authors and not necessarily those of the NHS, National Institute for Health Research, Department of Health or the UK Health Security Agency.

About the authors

Dr Atkins is a Chancellor's Fellow and Associate Professor whose work focuses on the epidemiology of antibiotic resistance and HIV.

Transparency declarations

Nothing to declare.

277

278 **Table 1:** Literature review of RSV-associated antibiotic use in the community, outpatient visits, and long-term care facilities.

Study first author (year) (reference)	Country	Population	Study Type	**Reported Outcome**					
				Rate of RSV-associated abx use in population		Abx use per RSV episode		RSV episodes per abx course	
				Number of abx courses in vc RSV cases / 1000 py	*Number of primary care abx courses attributable to RSV / 1000py*	*Number of abx courses / RSV-related primary care visit*	*% of vc RSV cases receiving abx courses*	*% of abx courses in study population with vc RSV*	*% of abx courses in background population attributable to RSV*
Ellis (2003) (21)	United States	Nursing home residents over 65 years presenting with fever or respiratory symptoms	Retrospective cohort	62.4 (43.4–81.3) (Not high risk) 75.6 (58.7–92.5) High risk)				3.3 (Not high risk) 2.8 (High risk)	
Caram (2009) (22)	United States	LTCF for older adults presenting with RTI	Prospective cohort				29% (2/7)		
Turner (2012) (19)	Thailand (Maela)	Children (birth to 2y) in refugee population presenting with	Prospective cohort	240 (95% CI 220–260)					

		pneumonia							
Meijboom (2013) (23)	Netherlands	Over 60y	Statistical analysis			0.75*			
Taylor (2016) (6)	United Kingdom	Children with recorded primary care antibiotic prescription	Statistical analysis of EHR		<6mo: 83.28 (55.47–102.65) 6-23mo: 119.16 (84.32–136.84) 2-4y: 74.95 (50.84–90.51) 5-17y: 10.91 (6.86–14.27)				<6mo: 19.7 6-23mo: 14.6 2-4y: 13.6 5-17y: 4.2†
Heikkinen (2017) (24)	Finland	Healthy children prospective study attending outpatient clinic (0-13y)	Prospective cohort				All: 54 (162/298) <1y: 91 (10/11) 1y: 63 (30/48) 2y: 64 (58/90) 3-6y: 48 (59/124) 7-13y:20 (5/25) **		
Smithgall (2020) (25)	United States	Household study of all ages presenting with ARI symptoms	Prospective household				24 (16/66)		
Toivonen (2020) (26)	Finland	Healthy children 0-2y presenting with ARI	Prospective birth cohort				35 (102/289) **		

Korsten (2021) (27)	Belgium/United Kingdom/Netherlands	Healthy community people 60+ years presenting with ARI	Prospective cohort				2/36 (6%)		
Fitzpatrick (2021) (7)	United Kingdom	Children under 5y with recorded community antibiotic prescribing	Statistical analysis of EHR						All: 6.92 (5.59, 8.25) <1y: 5.16 (3.91, 6.41) 1-4y: 5.80 (4.55, 7.04)

abx: antibiotic; py: person years; vc: virologically confirmed; EHR: electronic health records; ARI: acute respiratory infection

*calculated using excess antibiotic prescriptions and GP visits from the RSV season in the Netherlands (28)

**very low rate of hospitalizations so assumption that all antibiotic are community-prescribed

† from antibiotic prescriptions limited to those used against respiratory disease: broad spectrum penicillins, macrolides, tetracyclines

284

285

286

287

288 **Table 2**: Intervention assumptions. Each intervention was compared to status quo Palivizumab

289 administered seasonally to very high risk infants (9).

Intervention	Value	Notes
Monoclonal antibodies		
Delay between administration and protection (days)	None	(29)
Average period of protection (days)	275	(29)
Efficacy against symptomatic infection (%)	70.1 (52.3–81.0)	(30)
Uptake (%)	90%	Same as Palivizumab (9)
*Maternal vaccination**		
Average period of protection (days)	133.5 (119.6–146.1)	Same as estimated maternal immunity
Efficacy against symptomatic infection (%)	41.4 (4.1–64.2)	From Novavax Resvax trial (31)
Uptake (%)	60	Same as Tdap uptake in 3rd trimester (9)
Childhood / adolescent vaccination		

Delay between administration and protection (days)	11.4 (2.8–22.1)	Same as influenza antibody delay (32)
Average period of protection (days)	358.9 (350.7–364.7)	Assumed to be same as natural immunity (9)
Efficacy against any infection (%)	9-56%**	Assumed to be same as natural immunity (9)
Uptake (%)	90 (<1y) 45 (2-4y) 60 (5+y)	Assumed to be same as primary series (<1y) or LAIV (2+y) (9)

290 LAIV: live attenuated influenza vaccine

291 * Effect on infant; effect on mother assumed the same as childhood vaccination

292 ** Mean efficacy shown for illustrative purposes. Vaccination provides temporary protection against any disease,
293 before individual move into a reduced susceptibility state, consistent with natural exposure. The efficacy is not used
294 explicitly in the model, but a range can be calculated as $1 - [s + (1-s)r_i]$ for i=1,2,3, where s is the probability of
295 seroconversion after vaccination (s = 83.0% (75.0–88.0%)) and r_i is the risk of infection after i previous exposures
296 relative to after i-1 previous exposures (r_1 = 0.89 (0.85–0.93), r_2 = 0.81 (0.74–0.85), r_3 = 0.33 (0.31–0.37)).

297

298 **Table 3:** RSV-attributable antibiotic prescribing assumptions

	RSV-attributable antibiotic prescribing (courses per 100,000 person years, 95% CI)				
	0-5mo	**6-23mo**	**2-4y**	**5-17y**	**18+y**
Base case*					
Analysis A	8328 (5547-10265)	11916 (8432-13684)	7495 (5084-9051)	1091 (686-1427)	1091 (686-1427)
Sensitivity analysis**					

Analysis B	2758 (2086-3428)	3350 (2821-3918)	3635 (2876-4425)	559 (306-912)	559 (306-912)
Analysis C	2758 (2086-3428)	3350 (2821-3918)	3635 (2876-4425)	559 (306-912)	0 (0-0)

* assumption 18+y the same as 5-17y

**underlying rates <1 year (2,770, 95% CI: 2078, 3409);1-4 years (3,645 95% CI: 2,891, 4,400); ratio of 5-17y to 2-4y same as base case values.

Table 4: Predicted reduction in RSV-attributable primary care visits in England

Intervention*	**Vaccine/ mAb courses (per year)**	**Proportion of RSV-attributable primary care visits averted** (95% credible interval)**				
		0-5mo	**6-23mo**	**2-4y**	**5-17y**	**18+y**
Monoclonal antibodies						
MAB VHR S Seasonal Very high risk <8mo	2,218	0.064 (0.0094 – 0.12)	0.037 (-0.0033 – 0.076)	0.013 (-0.0031 – 0.029)	0.00011 (-4.6e-05 – 0.00041)	0.00023 (7.2e-05 – 4e-04)
MAB HR S Seasonal Very high risk <8mo High risk at birth	11,679	1.4 (1 – 1.6)	0.73 (0.55 – 0.87)	0.28 (0.2 – 0.33)	0.0016 (0.00038 – 0.0028)	0.00096 (7.6e-05 – 0.002)
MAB HR S+ Seasonal Very high risk <8mo High risk <6 mo	22,907	1.9 (1.5 – 2.3)	1.8 (1.4 – 2.1)	0.72 (0.55 – 0.84)	0.0088 (0.0043 – 0.013)	-0.004 (-0.0068 – -0.0016)
MAB ALL S Seasonal All infants at birth	252,581	27 (21 – 32)	4.4 (3.4 – 5.1)	1.6 (1.2 – 1.8)	0.037 (0.024 – 0.053)	0.17 (0.13 – 0.22)
MAB ALL S+ Seasonal	547,818	38 (30 – 44)	16 (12 – 19)	3.9 (3 – 4.5)	0.11 (0.077 – 0.15)	0.35 (0.24 – 0.44)

All infants <6 mo						
Maternal vaccination						
MAT S Seasonal 28-32wga pregnancy	165,257	7.7 (3.6 – 12)	-0.47 (-0.83 – -0.12)	-0.15 (-0.24 – -0.055)	0.055 (0.037 – 0.075)	0.28 (0.23 – 0.32)
MAT A Year round 28-32wga pregnancy	406,442	12 (6.1 – 17)	-0.11 (-0.42 – 0.14)	-0.26 (-0.42 – -0.11)	0.16 (0.12 – 0.21)	0.59 (0.51 – 0.68)
Childhood vaccination						
VAC INF S Seasonal Infants 2 months	251,162	24 (21 – 25)	5.5 (4.9 – 6.1)	0.6 (0.51 – 0.69)	-0.0034 (-0.017– 0.0079)	0.27 (0.2 – 0.34)
VAC INF A Year round Infants 2 months	617,724	34 (30 – 36)	13 (11 – 14)	1.3 (1.1 – 1.5)	0.006 (-0.026 –0.028)	0.48 (0.35 – 0.63)
VAC 2-4 S Seasonal Toddlers 2-4 years	917,008	0.91 (0.74 – 1.1)	0.55 (0.44 – 0.71)	21 (19 – 22)	0.6 (0.43 – 0.79)	1.2 (1 – 1.5)
Seasonal Children 5-9 years VAC 5-9 S	2,046,820	-0.32 (-0.43 – -0.14)	0.19 (0.11 – 0.34)	1.3 (1 – 1.6)	13 (8.2 – 16)	3.1 (2.6 – 3.7)
VAC 5-14 S Seasonal Children 5-14 years	4,093,640	-0.96 (-1.2 – -0.6)	-0.017 (-0.18 – 0.25)	2 (1.5 – 2.5)	26 (23 – 28)	7.5 (6.1 – 8.9)

* Monoclonal antibody programmes replace current Palivizumab programme, all other programmes are in addition.

**Proportion averted relative to the status quo strategy of Palivizumab seasonally administered to very high risk infants <1mo

mAb: monoclonal antibodies; wga: weeks gestational age



Figure 1: Averted antibiotic courses for each of the monoclonal antibodies (MAB), maternal vaccination (MAT) and age-targeted vaccination (VAC) interventions under base case assumptions (upper panel). Efficiency of each of the strategies at averting antibiotic courses (lower panel) under base case assumptions. Note the different y-axis scales.



Figure 2: Population impact of the reduction in antibiotic prescribing for each of the monoclonal antibodies (MAB), maternal vaccination (MAT) and age-targeted vaccination (VAC) interventions under base case assumptions.

References

1. Review on Antimicrobial Resistance. Tackling Drug-resistant Infections Globally: Final Report and Recommendations. 2016. 80 p.

2. Atkins KE, Lipsitch M. Can antibiotic resistance be reduced by vaccinating against respiratory disease? Lancet Respir Med. 2018 Nov;6(11):820–1.

3. Buckley BS, Henschke N, Bergman H, Skidmore B, Klemm EJ, Villanueva G, et al. Impact of vaccination on antibiotic usage: a systematic review and meta-analysis. Clin Microbiol Infect. 2019 Oct;25(10):1213–25.

4. Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017 Sep 2;390(10098):946–58.

5. Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017 Aug;2(8):e367–74.

6. Taylor S, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et al. Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK. BMJ Open. 2016 Jun 2;6(6):e009337.

7. Fitzpatrick T, Malcolm W, McMenamin J, Reynolds A, Guttmann A, Hardelid P. Community-Based Antibiotic Prescribing Attributable to Respiratory Syncytial Virus and Other Common Respiratory Viruses in Young Children: A Population-Based Time-series Study of Scottish Children. Clin Infect Dis. 2021 Jun 15;72(12):2144–53.

8. RSV Vaccine and mAb Snapshot [Internet]. [cited 2021 Oct 18]. Available from: https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/

9. Hodgson D, Pebody R, Panovska-Griffiths J, Baguelin M, Atkins KE. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis. BMC Med. 2020 Nov 18;18(1):348.

10. RSV Vaccine and mAb Snapshot [Internet]. [cited 2021 Oct 18]. Available from: https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/

11. [No title] [Internet]. [cited 2021 Oct 29]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/458469/Green_Book_Chapter_27a_v2_0W.PDF

12. Pouwels KB, Hopkins S, Llewelyn MJ, Walker AS, McNulty CA, Robotham JV. Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines. BMJ. 2019 Feb 27;364:l440.

360 13. Chae C, Davies NG, Jit M, Atkins KE. Effect of Pediatric Influenza Vaccination on
361 Antibiotic Resistance, England and Wales. Emerg Infect Dis. 2020 Jan;26(1):138–42.

362 14. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al.
363 Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-
364 resistant bacteria in the EU and the European Economic Area in 2015: a population-level
365 modelling analysis. Lancet Infect Dis. 2019 Jan;19(1):56–66.

366 15. Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, et al. Enumerating
367 the economic cost of antimicrobial resistance per antibiotic consumed to inform the
368 evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018 Aug
369 9;7:98.

370 16. Website [Internet]. Available from: https://www.oecd.org/health/health-systems/ #
371 International-Comparisons-of-Health-Prices-and-Volumes-New-Findings.pdf

372 17. Inflation calculator [Internet]. [cited 2021 Oct 28]. Available from:
373 https://www.bankofengland.co.uk/monetary-policy/inflation/inflation-calculator

374 18. The R Project for Statistical Computing [Internet]. [cited 2021 Sep 28]. Available from:
375 https://www.R-project.org

376 19. Turner C, Turner P, Cararra V, Lwe NE, Watthanaworawit W, Day NP, et al. A High
377 Burden of Respiratory Syncytial Virus Associated Pneumonia in Children Less than Two
378 Years of Age in a South East Asian Refugee Population [Internet]. Vol. 7, PLoS ONE.
379 2012. p. e50100. Available from: http://dx.doi.org/10.1371/journal.pone.0050100

380 20. de Kraker MEA, Lipsitch M. Burden of Antimicrobial Resistance: Compared to What?
381 Epidemiol Rev [Internet]. 2021 Mar 12; Available from:
382 http://dx.doi.org/10.1093/epirev/mxab001

383 21. Ellis SE, Coffey CS, Mitchel EF Jr, Dittus RS, Griffin MR. Influenza- and respiratory
384 syncytial virus-associated morbidity and mortality in the nursing home population. J Am
385 Geriatr Soc. 2003 Jun;51(6):761–7.

386 22. Caram LB, Brett Caram L, Chen J, William Taggart E, Hillyard DR, She R, et al.
387 Respiratory Syncytial Virus Outbreak in a Long-Term Care Facility Detected Using
388 Reverse Transcriptase Polymerase Chain Reaction: An Argument for Real-Time Detection
389 Methods [Internet]. Vol. 57, Journal of the American Geriatrics Society. 2009. p. 482–5.
390 Available from: http://dx.doi.org/10.1111/j.1532-5415.2008.02153.x

391 23. Meijboom MJ, Pouwels KB, Luytjes W, Postma MJ, Hak E. RSV vaccine in development:
392 assessing the potential cost-effectiveness in the Dutch elderly population. Vaccine. 2013
393 Dec 16;31(52):6254–60.

394 24. Heikkinen T, Ojala E, Waris M. Clinical and Socioeconomic Burden of Respiratory
395 Syncytial Virus Infection in Children. J Infect Dis. 2017 Jan 1;215(1):17–23.

25. Smithgall M, Maykowski P, Zachariah P, Oberhardt M, Vargas CY, Reed C, et al. Epidemiology, clinical features, and resource utilization associated with respiratory syncytial virus in the community and hospital. Influenza Other Respi Viruses. 2020 May;14(3):247–56.

26. Toivonen L, Karppinen S, Schuez-Havupalo L, Teros-Jaakkola T, Mertsola J, Waris M, et al. Respiratory syncytial virus infections in children 0-24 months of age in the community. J Infect. 2020 Jan;80(1):69–75.

27. Korsten K, Adriaenssens N, Coenen S, Butler C, Ravanfar B, Rutter H, et al. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J [Internet]. 2021 Apr;57(4). Available from: http://dx.doi.org/10.1183/13993003.02688-2020

28. Assink MDM, Kiewiet JP, Rozenbaum MH, Van den Berg PB, Hak E, Buskens EJ, et al. Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccination. Vaccine. 2009 Feb 11;27(7):1119–26.

29. Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T, et al. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants. Pediatr Infect Dis J. 2018 Sep;37(9):886–92.

30. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415–25.

31. Novavax, Inc. Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax™ for Prevention of RSV Disease in Infants via Maternal Immunization [Internet]. Novavax, Inc. 2019 [cited 2021 Oct 14]. Available from: https://www.globenewswire.com/news-release/2019/02/28/1744163/14446/en/Novavax-Announces-Topline-Results-from-Phase-3-PrepareTM-Trial-of-ResVax-for-Prevention-of-RSV-Disease-in-Infants-via-Maternal-Immunization.html

32. Baguelin M, Hoschler K, Stanford E, Waight P, Hardelid P, Andrews N, et al. Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation. PLoS One. 2011 Feb 23;6(2):e17074.

APPENDIX

Sensitivity Analysis Results



Figure S1: Sensitivity analysis (analysis B) of averted antibiotic courses for each of the monoclonal antibodies (MAB), maternal vaccination (MAT) and age-targeted vaccination (VAC) interventions (upper panel), and efficiency of each of the strategies at averting antibiotic courses (lower panel). Note the different y-axis scales.



Figure S2: Sensitivity analysis (analysis B) for the population impact of the reduction in antibiotic prescribing for each of the monoclonal antibodies (MAB), maternal vaccination (MAT) and age-targeted vaccination (VAC) interventions.



Figure S3: Sensitivity analysis (analysis C) of averted antibiotic courses for each of the monoclonal antibodies (MAB), maternal vaccination (MAT) and age-targeted vaccination (VAC) interventions (upper panel), and efficiency of each of the strategies at averting antibiotic courses (lower panel). Note the different y-axis scales.



Figure S4: Sensitivity analysis (analysis C) for the population impact of the reduction in antibiotic prescribing for each of the monoclonal antibodies (MAB), maternal vaccination (MAT) and age-targeted vaccination (VAC) interventions.